In recent studies on cefodizime, it may potentially have the capability of stimulating chemotactic activity of neutrophils and monocytes as well as the strong immuno-modulator. In turn, infection can result in a drastic change of mediators, which lead to initiate an immune response in an indirect way. With this background, we have studied to see if cefodizime can be a potential substance to induce an immunological function in dendritic cells and peritoneal macrophages.

In experimental process, dendritic cell and peritoneal macrophages were taken and mixed with 10μg/ml, 50μg/ml, 100μg/ml cefodizime and 1μg/ml IFN-γ10U/ml+LPS. These mixtures were then incubated for 4, 8, 12, 24 hrs to see if cytokines would be released in an analytical amount by assessing RT-PCR for IL-6 mRNA.

As a result, we have found that both may represent that both cells when treated with cefodizime can show an increase of cytokine. Accordingly, we can expect that cefodizime may induce the activation increase for macrophage, NK cell, CTL, B cell due to the increase of pro-inflammatory cytokine noted above. From these results, we will be able to say that cefodizime may be a potential immuno-modulator rather than an antibiotics itself.

IL-12 Expression by Cefodizime As an Immuno-modulator

Joo SeongSoo, Kwon Hee Seung, Oh WonSik, Lee DuikO

Division of Immunology, College of Pharmacy, ChungAng University, Seoul, Korea

Cefodizime has originally been developed for treating infections as antibiotics. However, according to some of recent studies, cefodizime, a third generation cephalosporin, may potentially have the capability of stimulating chemotactic activity of neutrophils and monocytes as well as the strong immuno-modulator. In this study, we studied to learn about the expressed effect of dendritic cells and macrophage. With this background, We have studied to see if cefodizime can be a potential substance inducing an immunological function in dendritic cells and peritoneal macrophages.

IL-12 activates NK cell and macrophage, and shows antiviral effect by excreting INF-γ. In vitro, total RNAs were extracted from murine dendritic cell at 4, 8, 12, 24 hr after the application of 10, 50, 100μg/ml of cefodizime without other stimulators. And we analyzed IL-12 mRNA using RT-PCR method. In conclusion, IL-12 mRNA was increased, and the results suggest that cefodizime activate TH1 cell induction, CTL differentiation as well as accelerating the increase of NK, LAK cell.

Tacrolimus and cyclosporine A inhibit both class I-restricted presentation pathway and class II-restricted presentation pathway of exogenous antigen.

Yang In-HoO, Lee YoungRan, Kim HyeonSeon, Lee JaeKwon, Im SunA, Li Hong, Han Kun, Song SukGil, Lee ChongKil

College of Pharmacy, Chungbuk National University

The main targets for the immunosuppressive calcineurin inhibitors, tacrolimus (FK-506) and cyclosporine A (CsA), have been considered to be activated T cells, but not antigen presenting cells (APCs). In the present study, we examined the effects of these drugs on the MHC-restricted presentation of exogenously added antigen, ovalbumin (OVA), in dendritic cells (DCs). Particulate form of OVA was efficiently captured, processed and presented on class I MHC molecules (cross-presentation) as well as on class II MHC molecules. Addition of tacrolimus and CsA, but not rafamycin, to cultures of DCs inhibited both the class I MHC-restricted presentation as well as the class II MHC-restricted presentation of exogenous OVA. Tacrolimus was much more effective in inhibiting both of the antigen presentation pathways than CsA. Inhibition of the exogenous OVA presentation by tacrolimus and CsA was not due to suppression of the expression of class I or class II MHC molecules on DCs. These results show that the immunosuppressive activity of tacrolimus and CsA is at least in part due to inhibition of antigen presenting function of professional APCs.

IL-1β Expression of Cefodizime on Dendritic cell and Macrophage

[PB4-2] [10/17/2002 (Thr) 13:30 - 16:30 / Hall C]

[PB4-3] [10/17/2002 (Thr) 13:30 - 16:30 / Hall C]

[PB4-4] [10/17/2002 (Thr) 13:30 - 16:30 / Hall C]